Levels of N‐terminal pro brain natriuretic peptide are enhanced in people with the uncomplicated metabolic syndrome: a case‐cohort analysis of the population‐based Casale Monferrato study

Bruno, Graziella; Barutta, Federica; Landi, Andrea; Pinach, Silvia; Caropreso, Paola; Mengozzi, Giulio; Baldassarre, S.; Fragapani, Salvatore; Civera, Stefania; Perin, Paolo Cavallo; Gruden, Gabriella

doi:10.1002/dmrr.2616

Cited by 4 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is likely due to differences among examined populations in the relative frequencies of metabolic syndrome components with opposite effects on NTproBNP, such as obesity and hypertension. Consistently, in a case-cohort analysis of the Casale Monferrato Study we provided evidence that, compared to people without any component of the metabolic syndrome, those in the uncomplicated phase of the syndrome, who had neither CVD/chonic renal failure nor diabetes, had yet increased NTproBNP values, even if they were normotensive [ 27 ].…”

Section: Discussionmentioning

confidence: 72%

“…Altogether, these findings suggest the alternative hypotheses that natriuretic peptides might act as either marker or risk factor of insulin-resistance mediated conditions, obesity, metabolic syndrome and diabetes [ 23 ]. However, data referring to the relationship between metabolic syndrome and natriuretic peptides are controversial, with studies showing both increased and reduced natriuretic peptides levels [ 24 – 27 ]. As regards to diabetes, increased plasma levels of NTproBNP have been identified as the strongest independent predictor of cardiovascular mortality even in people without pre-existing clinical CVD [ 28 – 30 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study

Baldassarre

Fragapani

Panero

et al. 2017

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

Background and aimsNTproBNP and BNP levels are reduced in obese subjects, but population-based data comparing the pattern of this relationship in the full spectrum of insulin-resistance mediated conditions, overweight/obesity, metabolic syndrome and diabetes, are limited.MethodsThe study-base were 3244 individuals aged 45–74 years, none of whom had heart failure, 1880 without diabetes and 1364 with diabetes, identified as part of two surveys of the population-based Casale Monferrato Study. All measurements were centralized. We examined with multiple linear regression and cubic regression splines the relationship between NTproBNP and BMI, independently of known risk factors and confounders. A logistic regression analysis was also performed to assess the effect of overweight/obesity (BMI ≥ 25 kg/m2), diabetes and metabolic syndrome on NTproBNP values.ResultsOut of the overall cohort of 3244 people, overweight/obesity was observed in 1118 (59.4%) non-diabetic and 917 (67.2%) diabetic subjects, respectively. In logistic regression, compared to normal weight individuals, those with a BMI ≥ 25 kg/m2 had a OR of 0.70 (95% CI 0.56–0.87) of having high NTproBNP values, independently of diabetes. As interaction between diabetes and NTproBNP was evident (p < 0.001), stratified analyses were performed. Diabetes either alone or combined with overweight/obesity or metabolic syndrome enhanced fourfold and over the OR of having high NTproBNP levels, while the presence of metabolic syndrome alone had a more modest effect (OR 1.54, 1.18–2.01) even after having excluded individuals with CVD. In the non-diabetic cohort, obesity/overweight and HOMA-IR ≥ 2.0 decreased to a similar extent the ORs of high NTproBNP [0.76 (0.60–0.95) and 0.74 (0.59–0.93)], but the association between overweight/obesity and NTproBNP was no longer significant after the inclusion into the model of HOMA-IR, whereas CRP > 3 mg/dl conferred a fully adjusted OR of 0.65 (0.49–0.86).ConclusionsNT-proBNP levels are lower in overweight/obesity, even in those with diabetes. Both insulin-resistance and chronic low-grade inflammation are involved in this relationship. Further intervention studies are required to clarify the potential role of drugs affecting the natriuretic peptides system on body weight and risk of diabetes.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study

Baldassarre

Fragapani

Panero

et al. 2017

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Taking into account these investigations along with our findings, it is possible to assume that the relationship between NPs and adiposity is bidirectional, with each factor influencing the levels of the other. Previous work has demonstrated inverse associations of NT‐proBNP with the development of metabolic syndrome (18,29) and diabetes (30). Although this study does not directly address metabolic syndrome and diabetes, it is likely that an increases in weight and thus lower levels of NPs contribute to a greater likelihood of these metabolic abnormalities.…”

Section: Discussionmentioning

confidence: 99%

Six‐year changes in N‐terminal pro‐brain natriuretic peptide and changes in weight and risk of obesity

Silva

Lazo

Tang

et al. 2021

Obesity

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to study the prospective association between N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) and changes in weight and obesity risk in a community‐based population.MethodsData from 9,681 participants from the Atherosclerosis Risk in Communities Study were analyzed at two time points 6 years apart. Among people without obesity at baseline, multivariable logistic regression models were used to examine the association between baseline levels of NT‐proBNP and incident obesity. A multivariable linear regression model was used to examine the association between changes in NT‐proBNP (visit 2 serum and visit 4 plasma samples) and changes in weight.ResultsThe prevalence of obesity increased from 28% to 35% in the 6‐year follow‐up period. Compared with individuals in the highest NT‐proBNP quartile, those in the lowest were more likely to have obesity at baseline (odds ratio 1.25; 95% CI: 1.08‐1.45) and, among people who did not have obesity at baseline, were more likely to develop obesity at follow‐up (odds ratio 1.35; 95% CI: 1.07‐1.69). Changes in NT‐proBNP were inversely associated with weight change.ConclusionsIn this prospective study, lower levels of NT‐proBNP were associated with higher risk of obesity, and changes in NT‐proBNP were inversely associated with changes in weight. This suggests that natriuretic peptides or their pathways may be potential targets in the treatment of obesity.

show abstract

“…Natriuretic peptides may have a role in the expansion of insulin resistance in conditions such as the metabolic syndrome, diabetes, and overweight or obesity [18]. The link among metabolic syndrome and natriuretic peptides is gaining interest, with research pointing to both higher as well as lower levels [19][20][21][22]. For those with no known cardiovascular disease, NTproBNP has been shown to be the most accurate predictor of mortality from cardiovascular causes [23].…”

Section: Introductionmentioning

confidence: 99%

Association of NTproBNP in metabolic syndrome

Dash

Sampson²,

Sahu

et al. 2022

ijhs

View full text Add to dashboard Cite

Aim: The association between NTpro BNP values and different biochemical and anthropometric parameters of metabolic syndrome patients and non-metabolic syndrome individuals are correlated here. Methods: The research involved 200 people aged 21 to 60 years old (100 control and 100 cases). The following measurements were taken- FBS, SBP, DBP, BMI, and lipid profile. Using multiple regression, we examined the correlation between NTproBNP and metabolic syndrome and non-metabolic syndrome patients. Correlation of Metabolic syndrome parameters with NTproBNP values are done. Result: NT pro BNP values are higher in metabolic syndrome patients in comparison to non-Metabolic syndrome patients. NTproBNP values are positively correlated with SBP, TG, LDL values in metabolic syndrome patients. Conclusion: NT pro BNP values are higher in metabolic syndrome patients in comparison to non-Metabolic syndrome patients.

show abstract

Levels of N‐terminal pro brain natriuretic peptide are enhanced in people with the uncomplicated metabolic syndrome: a case‐cohort analysis of the population‐based Casale Monferrato study

Cited by 4 publications

References 24 publications

NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study

NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study

Six‐year changes in N‐terminal pro‐brain natriuretic peptide and changes in weight and risk of obesity

Association of NTproBNP in metabolic syndrome

Contact Info

Product

Resources

About